BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
Follow-up results from Phase 2 trial suggested intolerable adverse events leading to discontinuation of previous…